• Explore /
  • Poster
  • / Dihydropyrimidine dehydrogenase gene (<em>DPYD</em>) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.

Abstract Poster

Authors

null

Nauman S Siddiqui

Tufts Medical Center, Boston, MA

Nauman S Siddiqui , Sneha Purvey , Ruchi Hamal , Lulu Zhang , Robert B. Diasio , Wasif M. Saif

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Pharmacology

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2576)

DOI

10.1200/JCO.2018.36.15_suppl.2576

Abstract #

2576

Poster Bd #

402

Abstract Disclosures

Similar Posters

First Author: Theodore John Wigle

First Author: Gul Ahmed

First Author: Garrett Rompelman

First Author: Jai Narendra Patel